1 BETA-CELL FAILURE IN DIABETES AND PRESERVATION BY ...

19
217. Ahrén B 2004 Sensory nerves contribute to insulin secretion by glucagon-like
peptide-1(GLP-1) in mice Am J Physiol Regul Integr Comp Physiol 286:R269-R272.
218. Nauck MA,El-Ouaghlidi A 2005 The therapeutic actions of DPP-IV inhibition are
not mediated by glucagon-like peptide-1 Diabetologia 48:608-611.
219. Ahrén B,Simonsson E,Larsson H,Landin-Olsson M,Torgeirsson H,Jansson
PA,Sandqvist M,Bavenholm P,Efendic S,Eriksson JW,Dickinson S,Holmes D
2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week
study period in type 2 diabetes Diabetes Care 25:869-875.
220. Ahrén B,Landin-Olsson M,Jansson PA,Svensson M,Holmes D,Schweizer A 2004
Inhibition of dipeptidyl peptidase-4 reduces glycemia,sustains insulin levels ,and reduces
glucagon levels in type 2 diabetes J Clin Endocrinol Metab 89:2078-2084.
221. Holst JJ ,Deacon CF 2005 Glucagon-like peptide – 1 mediates the therapeutic
actions of DPP-IV inhibitors Diabetologia 48:612-615.
222. Drucker DJ 2006 DPP-4 inhibitors in the management of type 2 diabetes lide
presentation). Mechanisms in Medicine Inc.,pag.59.
223. Ahrén B 2000 Autonomic regulation of islet hormone secretion : implications for
health and disease . Diabetologia 43:393-410.
224. Filipsson K,Kvist Reimer M,Ahrén B 2001 The neuropeptide pituitary adenylate
cyclase-activating polypeptide and islet function Diabetes 53:1959-1969.
225. .Ahrén B ,Hughes TE 2005 Inhibition of DPP-IV augments insulin secretion in
response to exogenously administered Glucagon-like peptide-1,Glucose-dependent
insulinotropic polypeptide,Pituitary adenylate cyclase-activating polypeptide,and Gastrinreleasing
peptide in mice. Endocrinology 146:2025-2029.
226. Mest H-J ,Mentlein R 2005 Dipeptidyl peptidase inhibitors as new drugs for the
treatment of type 2 diabetes Diabetologia 48:616-620.
227. Mu J,Woods J,Zhou Y-P,Roy RS,Li Z,Zycband E,Feng Y,Zhu L,Li C,Howard
AD,Moller DE,Thornberry NA,Zhang BB 2006 Chronic inhibition of Dipeptidyl
peptidase –4 with a sitagliptin analog preserves pancreatic β--cell mass and function in a
rodent model of type 2 diabetes Diabetes 55:1695-1704.
228. Herman GA,Stevens C,Van Dyck K,Bergman A,Yi B,De Smet M,Snyder K,Hilliard
D,Tanen M,Tanaka W,Wang AQ,Zeng W,Musson D,Winchell G,Davies MJ,Ramael
S,Gottesdiener KM,Wagner JA 2005 Pharmacokinetics and pharmacodynamics of
sitagliptin ,an inhibitor of dipeptidyl peptidase IV,in healthy subjects :results from tworandomized,double-blind,placebo-controlled
studies with single oral doses. Clin Pharmacol
Ther 78:675-688